Active comparator trial! Always my favorite.  Lots of fun topics in this one, including noninferiority trials, crafty endpoints, and PROs.  Check it out and let me know what you think! @ebrheum 

Another day, another lupus trial, another round of endpoint shenanigans.  Why does that matter? How big is the benefit from belimumab in SLE nephritis? Will this save lives and prevent ESRD / RRT? I try to tackle these issues this week and (hopefully) avoid getting myself in trouble.  Hope you enjoy the episode!  Let me know what you think @ebrheum on twitter! 

Great paper to discuss this week - one that may be too good to believe? I highly recommend checking out the pdf first (ebrheum.com/twts) - their graphics are wonderful and do a great job of conveying their message.  Also, check out the "2-5-10" rule that I referenced!  This is required reading for anyone who rotates with me - easily one of the most useful EBM papers I have ever read. 

Quick podcast this week that expands on issues I discuss in Episode 55.  Go back and listen to that one first if you have time!  I think this is an important issue and it's one I'd like to highlight.  Let me know what you think @ebrheum and please share with friends! 

The podcast is back!  I tune in briefly here to explain where I've been, what I'm doing, and where this will be headed. Feel free to skip right ahead if you'd rather just dig back in! 

PEXIVAS has landed!  This week I go over the trial and my take on it's results.  Impressive undertaking that answered two questions for a subset of patients with AAV - well worth the time to kick back and read the trial in full. Let me know what you think about the podcast @ebrheum! 

(Yet) another RCT this week!  Nice investigator initiated trial with many wonderful strengths and a few crippling flaws. Great opportunity to think about a common problem in practice as well as a separate common problem in trials! 

This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE.  Great to see a new drug in this disease state; interesting to think through how these trials played out.  Get the papers and the pod at ebrheum.com and follow me @ebrheum if you'd like to share feedback! 

Happy New Year!  This week Dr. Anisha Dua (@anisha_dua) and Dr. Sarah Fantus (@sarahfantus) debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line."  Please be sure to VOTE AGAIN on twitter (@ebrheum) after you have listened! 

This week I go back to a topic from episode 42, the SENSCIS trial and nintedanib for SSc-ILD.  The way this medication has been received and a recent article I wrote for The Rheumatologist gave me a nice jumping off point to cover a few more issues from this. Be sure to follow me @EBRheum to let me know what you think! The corresponding article is available here: https://www.the-rheumatologist.org/article/fda-approves-nintedanib-for-ssc-ild-but-temper-your-expectations/